| (Values in U.S. Thousands) | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 |
| Sales | 330 | 470 | 6,460 | 6,170 | 17,060 |
| Sales Growth | -29.79% | -92.72% | +4.70% | -63.83% | +13.58% |
| Net Income | -23,800 | -18,180 | -21,150 | 8,240 | 15,690 |
| Net Income Growth | -30.91% | +14.04% | -356.67% | -47.48% | +515.29% |
Vaccitech Plc ADR (VACC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Vaccitech plc is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Vaccitech plc is based in OXFORD, United Kingdom.